Neurogene (NGNE) Q4 2025 earnings summary

Executive summary

• Achieved full enrollment and dosed over 50% of participants in the Embolden registrational trial for NGN-401, with dosing completion expected in Q2 2026.

• NGN-401 received FDA Breakthrough Therapy designation based on positive interim safety and efficacy data from the Phase 1/2 trial.

• Commercial manufacturing scale confirmed to match clinical scale, eliminating need for comparability studies for BLA submission.

• Strong cash position of $269.0 million as of December 31, 2025, expected to fund operations through Q1 2028.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $269.0 million at year-end 2025.

• R&D expenses rose to $75.0 million in 2025 from $60.9 million in 2024, mainly due to increased Rett syndrome trial costs and headcount.

• G&A expenses increased to $28.3 million in 2025 from $22.6 million in 2024, driven by higher stock-based compensation and headcount.

• Net loss widened to $90.4 million in 2025 from $75.1 million in 2024.

• Revenue under licensing agreements was $0.9 million in 2025.

Outlook and guidance

• Dosing in the Embolden trial to be completed in Q2 2026, with updated interim safety and efficacy data expected mid-2026.

• Process Performance Qualification (PPQ) campaign to begin mid-2026, supporting BLA readiness.

• Cash runway projected through Q1 2028.